This page shows the latest Neuraceq news and features for those working in and with pharma, biotech and healthcare.
Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment
CHMP backs Piramal's Alzheimer's imaging agent. Neuraceq recommended for approval in Europe. ... Piramal acquired rights to Neuraceq from Bayer in 2012, saying at the time it expected the global market for PET imaging agents for AD to reach $1.5bn at peak
Deal will assign worldwide rights to Bayer's imaging portfolio to a new Piramal company
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....